Partnering with a science-driven CRO/ CDMO, offering a wide range of solutions from target identification to clinical trials in patients , can effectively shorten the time for bringing new drugs to market.
NUVISAN provides end-to-end solutions including high throughput screening with a 3-million-compound library, lead optimization, translational research, GLP toxicology studies as well as preclinical and clinical studies, bioanalytical testing and clinical trial supply.
Decades of pharma expertise and our broad portfolio of solutions have helped develop strong partnerships with the top 10 pharmaceutical companies, newly settled biotechs, and venture capitals.
